KRAS Cell Panel Screening Service
In troduction
KRAS, a critical oncogene in human cancers, has been the focal point for therapeutic research given its prominent role in non-small cell lung cancer (NSCLC) and other malignancies. Its mutations are a common driving factor in tumorigenesis, particularly due to its role in disrupting cellular signaling pathways such as the RAF/MEK/ERK and PI3K/AKT/mTOR pathways. Despite the recognized significance of KRAS in cancer, therapeutic options directly targeting KRAS have been limited, prompting ongoing research and technological advancements in this domain. Creative Biolabs has pioneered a robust solution in addressing this challenge through the KRAS Cell Panel Screening Service.
Fig.1 KRAS signal pathway.1,3
KRAS Cell Panel Screening Service at Creative Biolabs
At Creative Biolabs, we offer a cutting-edge KRAS cell panel screening service designed to aid in the discovery and development of effective inhibitors targeting KRAS mutations. Our service harnesses advanced in vitro models and assay technologies to evaluate the efficacy of drug candidates against a comprehensive panel of cancer cell lines harboring KRAS mutations. This service is critical for identifying compounds with potential therapeutic value, offering an essential step in the drug development pipeline. Creative Biolabs leverages proprietary platforms and highly specialized expertise to provide actionable insights into how drug candidates interact with KRAS-mutant cells.
Comprehensive Content in Our Cell Panel Screening Service
Our KRAS cell panel screening encompasses several key components:
Cell Line Diversity
We maintain a diverse collection of over 160 human cancer cell lines representing various tumor types and genetic backgrounds, including all major KRAS mutations (G12D, G12C, G13D, and Q61H). This diversity ensures that screening results are broadly applicable across different KRAS-mutated cancers.
Assay Platforms
High-throughput screening data is analyzed with sophisticated bioinformatics tools to elucidate compound mechanisms of action and identify potential biomarkers for drug responsiveness.
Data Analysis and Bioinformatics
With the capability to process a vast array of compounds rapidly, our assay panels are designed for high-throughput screening, accommodating both broad and focused research needs.
Customizable Screening Option
Clients can choose from single-agent screening or combination studies to explore synergistic effects between different therapeutic agents.
Applications of Our KRAS Cell Panel Screening
The applications for our screening service span the entire drug discovery process:
-
Lead Compound Identification: Pinpointing potential drug candidates that effectively inhibit KRAS-mutant cell proliferation.
-
Mechanistic Studies: Understanding how compounds modulate KRAS activity and downstream signaling pathways, such as the RAF/MEK/ERK and PI3K/AKT pathways.
-
Biomarker Discovery: Identifying genetic or protein markers that correlate with drug sensitivity or resistance.
-
Combination Therapy Evaluation: Investigating the efficacy of drug combinations to enhance therapeutic outcomes while minimizing resistance.
Benefits of Our Service
Creative Biolabs' comprehensive KRAS Cell Panel Screening Service offers several advantages:
High Precision and Accuracy
Using state-of-the-art technology, our service ensures high specificity in measuring compound interactions with KRAS.
Broad Cell Line Diversity
Employing over 160 cell lines allows for a more representative assessment of compound efficacy across different cancer types.
Rapid Turnaround Time
Our semi-automated processing facilitates faster data acquisition, allowing researchers to expedite their drug discovery process.
Scientific Backing
|
Summary
|
KRAS Cell-based Screening is supported by robust scientific methodologies documented in peer-reviewed studies. For instance, compounds like 0375-0604 have demonstrated significant potential in targeting KRAS mutations. This compound binds with KRAS mutants such as KRASG12D, KRASG12C, and KRASQ61H, inhibiting downstream signaling pathways and inducing apoptosis in cancer cells, while sparing normal cells.
|
|
Result:
|
Fig.2 Compound 0375-0604 induce Cell cycle arrest and apoptosis in three NSCLC cell lines.2,3
|
Frequently Asked Questions
Q1: What type of compounds can be screened in your KRAS service?
A1: Our screening service can evaluate small molecules, peptides, and other compound types that target KRAS and its downstream pathways.
Q2: How does the screening service impact the drug discovery process?
A2: By providing detailed interaction profiles and efficacy data, our service accelerates the optimization and development of KRAS-targeted therapies, reducing drug development timelines significantly.
Creative Biolabs remains committed to innovation in cancer treatment, leveraging our expertise in biological sciences and technology to bring forth solutions that meet the challenges posed by KRAS-driven cancers. Our KRAS Cell Panel Screening Service exemplifies our dedication to scientific excellence and our commitment to aiding the global effort in combating cancer through innovative therapeutic strategies.
References
-
Huang, Lamei, et al. "KRAS mutation: from undruggable to druggable in cancer." Signal transduction and targeted therapy 6.1 (2021): 386.
-
Xie, Chun, et al. "Identification of a new potent inhibitor targeting KRAS in non-small cell lung cancer cells." Frontiers in pharmacology 8 (2017): 823.
-
Distributed under Open Access License CC BY 4.0, without modification.
For Research Use Only | Not For Clinical Use
